Orvosi Hetilap
Volume/Issue:
Volume 156: Issue 6
Helicobacter pylori – 2014
Author: György Miklós Buzás 1
View More View Less
  • 1 Ferencvárosi Egészségügyi Szolgáltató KKNp Kft. Budapest Mester utca 45. 1095
DOI:
https://doi.org/10.1556/oh.2015.30097
Page Count:
203–210
Publication Date:
01 Feb 2015
Online Publication Date:
01 Feb 2015
Article Category:
Research Article
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00
Purchase Online Subscription

  • Purchase article

    USD  $25.00

  • 1 year subscription (Individual Only)

    USD  $1,070.00

A szerző az utóbbi 2 év Helicobacter pylori-kutatás eredményeit tekinti át. A genetikusok több mint ezer mikro-RNS közül azonosítottak néhány csoportot, amelyek gyomorrákban vagy rákmegelőző állapotokban túl- vagy alulszabályozottak: ezek lehetnek a jövő markerei vagy terápiás célpontjai. A metaanalízisek 95 közleménnyel gazdagodtak: több dolgozatban kimutatták a Helicobacter pylori és a nyelőcső-, vastagbél-, hasnyálmirigy- és májrák asszociációját, bár a kapcsolat ezek egyikében sem olyan erős, mint a fertőzés és a gyomorrák kapcsolata. Az Epstein–Barr-vírus a gyomorrákok 10%-ában mutatható ki; a fertőzés gyakoriságát normális nyálkahártyában, krónikus gastritisben és peptikus fekélyben jelenleg kutatják. Az eradikációs kezelések eredményei gyakran elégtelenek: néhány módszer kerül bemutatásra, amelyekkel azokat optimalizálni lehet. 2013-ban az Európai Helicobacter Munkacsoport kezdeményezte egy páneurópai regiszter összeállítását: eddig 5792 beteg adatait regisztrálták, kimutatva, hogy több terápiás módszer nem elég hatékony. 2013-ban indult útjára az Egészséges Gyomor Kezdeményezés azzal a céllal, hogy az egészséges egyénekben és gyomorbetegségekben végzett kutatásokat világszerte támogassák, hogy azok mielőbb alkalmazásra kerüljenek. Orv. Hetil., 2015, 156(6), 203–210.

  • Hagymási, K., Tulassay, Zs.: Helicobacter pylori infection: new pathogenetic and clinical aspects. World J. Gastroenterol., 2014, 20(21), 6386–6399.

  • Yang, J. C., Lu, C. W., Lin, C. J.: Treatment of Helicobacter pylori infection: current status and future concepts. World J. Gastroenterol., 2014, 20(18), 5283–5293.

  • Talebi Bezmin Abadi, A.: Therapy of Helicobacter pylori: present medley and future prospective. BioMed Res. Inter., 2014, 2014, 124607.

  • Igaz, I., Igaz, P.: Tumor surveillance by circulating microRNAs: a hypothesis. Cell. Mol. Life Sci., 2014, 71(21), 4081–4087.

  • Ishiguro, H., Kimura, M., Takeyama, H.: Role of microRNAs in gastric cancer. World J. Gastroenterol., 2014, 20(19), 5694–5699.

  • Zabaleta, J.: MicroRNA: a bridge from H. pylori infection to gastritis and gastric cancer development. Front. Genet., 2012, 3, 294.

  • Chang, H., Kim, N., Park, J. H., et al.: Different microRNA expression levels in gastric cancer depending on Helicobacter pylori infection. Gut Liver, 2014 Jun 18. doi: 10.5009/gnl13371. [Epub ahead of print]

  • Stánitz, É., Juhász, K., Tóth, Cs., et al.: Evaluation of microRNA expression pattern of gastric adenocarcinoma associated with socioeconomic, environmental and lifestyle factors in Northwestern Hungary. Anticancer Res., 2013, 33(8), 3195–3200.

  • Wang, X. W., Wu, Y., Wang, D., et al.: MicroRNA network analysis identifies key microRNAs and genes associated with precancerous lesions of gastric cancer. Genet. Mol. Res., 2014, 13(4), 8695–8703.

  • Zhang, Z. Y., Dai, Z. L., Yin, X. W., et al.: Meta-analysis shows that circulating tumor cells including circulating microRNAs are useful to predict the survival of patients with gastric cancer. BMC Cancer, 2014, 14, 733.

  • Moher, D., Liberati, A., Tetzlaff, J., et al., The PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J. Clin. Epidemiol., 2009, 62(10), 1006–1012.

  • Xie, F. J., Zhang, Y. P., Zheng, Q. Q., et al.: Helicobacter pylori infection and esophageal cancer risk: an updated meta-analysis. World J. Gastroenterol., 2013, 19(36), 6098–6107.

  • Nie, S., Chen, T., Yang, X., et al.: Association of Helicobacter pylori infection with esophageal adenocarcinoma and squamous cell carcinoma: a meta-analysis. Dis. Esophagus, 2014, 27(7), 645–653.

  • Wu, Q., Yang, Z. P., Xu, P., et al.: Association between Helicobacter pylori infection and the risk of colorectal neoplasia: a systematic review and meta-analysis. Colorectal Dis., 2013, 15(7), e352–e364.

  • Rokkas, T., Sechopoulos, P., Pistiolas, D., et al.: The relationship of Helicobacter pylori infection and colon neoplasia, on the basis of meta-analysis. Eur. J. Gastroenterol. Hepatol., 2013, 25(11), 1286–1294.

  • Chen, Y. S., Xu, S. X., Ding, Y. B., et al.: Helicobacter pylori infection and the risk of colorectal adenoma and adenocarcinoma: an updated meta-analysis of different testing methods. Asian Pac. J. Cancer Prev., 2013, 14(12), 7613–7619.

  • Wang, F., Sun, M. Y., Shi, S. L., et al.: Helicobacter pylori infection and normal colorectal mucosa-adenomatous polyp-adenocarcinoma sequence: a meta-analysis of 27 case-control studies. Colorectal Dis., 2014, 16(4), 246–252.

  • Xiao, M., Wang, Y., Gao, Y.: Association between Helicobacter pylori infection and pancreatic cancer development: a meta-analysis. PLoS ONE, 2013, 8(9), e75559.

  • Wang, Y., Zhang, F. C., Wang, Y. J.: Helicobacter pylori and pancreatic cancer risk: a meta-analysis based on 2,049 cases and 2,861 controls. Asian Pac. J. Cancer Prev., 2014, 15(11), 4449–4454.

  • Zhou, D., Wang, J. D., Weng, M. Z., et al.: Infection of Helicobacter spp. in the biliary system are associated with biliary tract cancer: a meta-analysis. Eur. J. Gastroenterol. Hepatol., 2013, 25(4), 447–454.

  • Plummer, M., Franceschi, S., Vignat, J., et al.: Global burden of gastric cancer attributable to H. pylori. Int. J. Cancer, 2015, 136(2), 487–490.

  • Malfertheiner, P., Megraud, F., O’Morain, C., et al., The European Helicobacter Study Group (EHSG): Management of Helicobacter pylori infection – the Maastricht IV/Florence Consensus report. Gut, 2012, 61(5), 646–664.

  • Kim, S. G., Jung, H. K., Lee, H. L., et al., Korean College of Helicobacter pylori and Upper Gastrointestinal Research: Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 Revised edition. Korean J. Gastroenterol., 2013, 62(1), 3–26.

  • Murphy, G., Pfeiffer, R., Camargo, C., et al.: Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology, 2009, 137(3), 824–833.

  • Truong, C. D., Feng, W., Li, W., et al.: Characteristics of Epstein-Barr virus-associated gastric cancer: a study of 235 cases at a comprehensive cancer center in U.S.A. J. Exp. Clin. Cancer Res., 2009, 28, 14.

  • De Souza, C. R., de Oliveira, K. S., Ferraz, J. J., et al.: Occurrence of Helicobacter pylori and Epstein-Barr virus infection in endoscopic and gastric cancer patients from Northern Brazil. BMC Gastroenterol., 2014, 14, 179.

  • Gagneux-Brunon, A., Suy, F., Pouvaret, A., et al.: Acute acalculous cholecystitis, a rare complication of Epstein-Barr virus primary infection: report of two cases and review. J. Clin. Virol., 2014, 61(1), 173–175.

  • Ryan, J. L., Shen, Y. J., Morgan, D. R., et al.: Epstein-Barr virus infection is common in inflamed gastrointestinal mucosa. Dig. Dis. Sci., 2012, 57(7), 1887–1898.

  • Cárdenas-Mongragón, M. G., Carreón-Talavera, R., Camorlinga-Ponce, M., et al.: Epstein Barr virus and Helicobacter pylori co-infection are positively associated with severe gastritis in pediatric patients. PLoS ONE, 2013, 8(4), e62850.

  • Matsusaka, K., Funata, S., Fukayama, M., et al.: DNA methylation in gastric cancer, related to Helicobacter pylori and Epstein-Barr virus. World J. Gastroenterol., 2014, 20(14), 3916–3926.

  • Nishikawa, J., Yoshiyama, H., Iizasa, H., et al.: Epstein-Barr virus in gastric carcinoma. Cancers (Basel), 2014, 6(4), 2259–2274.

  • Graham, D. Y., Lee, Y. C., Wu, M. S.: Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin. Gastroenterol. Hepatol., 2014, 12(2), 177–186. e3.

  • Molina-Infante, J., Gisbert, J. P.: Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World J. Gastroenterol., 2014, 20(30), 10338–10347.

  • Fallone, C. A., Barkun, A. N., Szilágyi, A., et al.: Prolonged treatment duration is required for successful Helicobacter pylori eradication with proton pump inhibitor triple therapy in Canada. Can. J. Gastroenterol., 2013, 27(7), 397–402.

  • Dang, Y., Reinhardt, J. D., Zhou, X., et al.: The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: A meta-analysis. PLoS ONE, 2014, 9(11), e111030.

  • Russo, F., Linsalata, M., Orlando, A.: Probiotics against neoplastic transformation of gastric mucosa: effects on cell proliferation and polyamine metabolism. World J. Gastroenterol., 2014, 20(37), 13258–13272.

  • Makipour, K., Friedenberg, F. K.: The potential role of N-acetylcysteine for the treatment of Helicobacter pylori. J. Clin. Gastroenterol., 2011, 45(10), 841–843.

  • Karbasi, A., Hossein Hosseini, S., Shohrati, M., et al.: Effect of oral N-acetyl cysteine on eradication of Helicobacter pylori in patients with dyspepsia. Minerva Gastroenterol. Dietol., 2013, 59(1), 107–112.

  • Wang, B., Wang, Y. H., Lv, Z. F., et al.: Efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. Helicobacter, 2014 Nov 8. doi: 10.111/hel.12180. [Epub ahead of print]

  • Oderda, G., Scherbakov, P., Bontems, P., et al.: Results from the Pediatric European Register for treatment of Helicobacter pylori (PERTH). Helicobacter, 2007, 12(2), 150–156.

  • McNicholl, A. G., Gasbarrini, A., Tepes, B., et al.: Pan-European registry on H. pylori management (Hp-EuReg): first line treatments. Helicobacter, 2014, 19(Suppl. 1), 129.

  • McNicholl, A. G., Gasbarrini, A., Tepes, B., et al.: Pan-European Registry on H. pylori management (Hp-EuReg): rescue treatments. Helicobacter, 2014, 19(Suppl. 1), 130.

  • Gisbert, J. P., Pajares, J. M.: Esomeprazole-based therapy in Helicobacter pylori eradication: a meta-analysis. Dig. Liver Dis., 2004, 36(4), 253–259.

  • Wang, X., Fang, J. Y., Lu, R., et al.: A meta-analysis: comparison of esomeprazole and other proton pump inhibitors in eradicating Helicobacter pylori. Digestion, 2006, 73(2–3), 178–186.

  • McNicholl, A. G., Linares, P. M., Nyssen, O. P., et al.: Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment. Pharmacol. Ther., 2012, 36(5), 414–425.

  • Nagajara, V., Eslick, G. D.: Evidence-based asessment of proton-pump inhibitors in Helicobacter pylori eradication: a systematic review. World J. Gastroenterol., 2014, 20(40), 14527–14536.

  • Malfertheiner, P.: Preface. Healthy Stomach Initiative: the stomach in health and disease. Dig. Dis., 2014, 32(3), 185.
Cover Orvosi Hetilap
Orvosi Hetilap
Print ISSN:
0030-6002
Online ISSN:
1788-6120
Keywords:
Epstein–Barr-vírus; Helicobacter pylori ; metaanalízis; mikro-RNS; páneurópai regiszter; Epstein–Barr virus; Helicobacter pylori ; metaanalysis; microRNA; pan-European registry

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Jul 2020 11 3 1
Aug 2020 6 0 0
Sep 2020 9 0 0
Oct 2020 22 0 0
Nov 2020 7 2 0
Dec 2020 14 0 0
Jan 2021 3 0 0